Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics develops targeted immunotherapies that attack solid tumors and aim to enhance the immune system's ability to combat cancer. The company is involved in clinical trials for its neural stem cells engineered to carry an oncolytic virus for treating recurrent high-grade glioma.

Calidi Biotherapeutics

Calidi Biotherapeutics | 2,536 followers on LinkedIn. Calidi Biotherapeutics is a clinical-stage biopharmaceutical company | Calidi Biotherapeutics is a clinical-stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell-based platforms.

Quality Assurance Leader in Biotech/Pharma

Violet M. Carvalho

Chief Financial Officer

Andrew Jackson

Cofounder and Vice Chairman of Board of Directors Calidi Biotherapeutics

Scott Leftwich

Chief Business and Revenue Officer | Global

Steve Thesing

👏 Calidi Biotherapeutics recognizes Wendy Pizarro, Esq. , our Chief Legal Officer and Chief Diversity Officer, as a speaker today, October 21, 2024, at the San Diego Precision in Clinical Trials Summit in San Diego, CA. Sherri Monroe She will be speaking on Diversity, Equity and Inclusion Strategies in Clinical Trials and Patient Recruitment. Please reach out to her if you will be attending! #calidi #clinicaltrials #PCTSUMMIT #DEI #endcancer $CLDI

Calidi Biotherapeutics ' Chief Business Officer, Steve Thesing , recently interviewed with Dave Gentry , CEO of RedChip Companies , discussing Calidi's cancer therapies and their place in the future of oncology. Click below for the full interview: #calidi #oncology #virotherapy #endcancer $CLDI

Congratulations to Calidi Biotherapeutics ' Chief Legal Officer and Chief Diversity Officer, Wendy Pizarro, Esq. , for being awarded as a "2024 DEIA Visionary" by the L.A. Times B2B Publishing for her advocacy on health equity in innovative clinical trials. Read more here: https://lnkd.in/gd5v6aVf #DEI #healthequity #deia #indigenouspeoplesday

Calidi Biotherapeutics is thrilled to announce FDA Clearance of the Northwestern University IND Application for Calidi's NeuroNova (CLD-101) Clinical Trial in Newly Diagnosed High-Grade Glioma. Congratulations to the NWU and Calidi teams! Read more below: #calidi #IND #clinicaltrial #virotherapy #neuronova $CLDI #glioblastoma #highgradeglioma #braincancer

Missed Our Virtual Presentation? Watch the Replay Now! Yesterday, we at Calidi Biotherapeutics hosted an exciting virtual presentation diving deep into the groundbreaking science and innovative technology we’re developing to combat cancer. If you missed it, don’t worry! You can catch the full replay and discover how our pioneering approaches are transforming the future of cancer treatment. Watch the Replay Here: https://lnkd.in/gnGR7Fmf Join us on this journey towards a world free from the threat of cancer. Your support and curiosity drive our mission forward! #CalidiBio #CancerResearch #Biotechnology #Innovation #Science #Healthcare

Join Us for an Exciting Webinar: Calidi’s Groundbreaking Cancer Treatment 📅 Date: September 11th 🕓 Time: 4:15 PM ET Discover the future of cancer treatment with Calidi! Our developmental drug targets and destroys cancer cells throughout the body while leaving healthy cells unharmed. Don’t miss this opportunity to learn more about this revolutionary therapy. 🔗 Register now: #calidi #virotherapy #endcancer $CLDI

Calidi Biotherapeutics was recently featured in an article by Fred Grier with the San Diego Business Journal , highlighting the launch of our new subsidiary, Nova Cell. Read more below! #calidi #novacell #stemcells #biotech #sandiego $CLDI

📣 Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results. Read more below! #calidi #virotherapy #stemcells #biotech $CLDI

Calidi Biotherapeutics is proud to announce the launch of our new subsidiary, Nova Cell, and a $3 million aggregate investment from Dr. Ronald Rigor. Dr. Rigor, an accomplished Board-Certified Dermatologist, Internal Medicine, and Stem Cell Therapy expert has taken a significant step to advance regenerative medicine by investing in Nova Cell. “As the founder of one of the largest and fastest growing stem cell centers in the Philippines, I am delighted to partner with and invest in Nova Cell. This is a fantastic opportunity to provide best-in-class stem cell therapy treatments which could meet a huge unmet need in the Philippines. We look forward to bringing Nova Cell’s extensive experience in stem cell therapy production to provide innovative therapies to patients and to elevate the health and wellness industry in the Philippines.” - Dr. Rigor Read more below: #stemcell #calidi #NovaCell $CLDI

Calidi Biotherapeutics recently announced the issuance of a new U.S. patent covering our novel SuperNova technology! “This latest patent granted to Calidi covering meaningful features of our SuperNova platform represents an important milestone, as we prepare to advance CLD-201 into the clinic." - Allan Camaisa, CEO and Chairman. Read more below: #calidi #patent #SuperNova #virotherapy #stemcells $CLDI

	Dec '21	Dec '22	Dec '23
account payables	63.84K -	2.27M 3,457.39%	2.88M 26.68%
accumulated other comprehensive income loss	-1K -	-14K 1,300%	-47K 235.71%
cash and cash equivalents	1.06M -	472K 55.58%	2.05M 334.11%
cash and short term investments	1.06M -	472K 55.58%	2.05M 334.11%
common stock	230.01M -	2K 100.00%	4K 100%
deferred revenue	-5.14M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt	43K -	447K 939.53%	2.06M 360.85%
long term investments	230.00M -		230K -
net debt	4.12M -	5.52M 33.94%	5.19M 5.96%
net receivables			1.36M -
other assets	1 -
other current assets	420.91K -	314K 25.40%	894K 184.71%
other current liabilities	-4.79M -	35.18M 834.25%	5.43M 84.56%
other liabilities
other non current assets	-304.06K -	725K 338.44%	143K 80.28%
other non current liabilities	16.00M -		5.96M -
othertotal stockholders equity	1K -	19.93M 1,992,700%	91.38M 358.55%
preferred stock		9.60M -
property plant equipment net	585K -	1.09M 85.64%	5.34M 391.99%
retained earnings	-14.69M -	-70.36M 379.02%	-99.57M 41.53%
short term debt	5.14M -	5.54M 7.84%	1.92M 65.30%
short term investments
tax assets
tax payables
total assets	231.77M -	2.60M 98.88%	10.02M 285.79%
total current assets	1.48M -	786K 47.02%	4.30M 447.46%
total current liabilities	410.99K -	42.99M 10,359.99%	10.23M 76.20%
total debt	5.18M -	5.99M 15.58%	7.24M 20.84%
total investments	230.00M -		230K -
total liabilities	16.45M -	43.44M 164.03%	18.25M 57.97%
total liabilities and stockholders equity	231.77M -	2.60M 98.88%	10.02M 285.79%
total non current assets	230.29M -	1.81M 99.21%	5.72M 215.63%
total non current liabilities	16.04M -	447K 97.21%	8.02M 1,694.63%
total stockholders equity	215.32M -	-40.84M 118.97%	-8.23M 79.84%

COM:CALIDIBIO

Calidi Biotherapeutics

Last Close

2.15

22/11 21:00

Market Cap

37.48M

Beta: -

Volume Today

1.48M

Avg: -

Preview